Johnson & Johnson (NYSE:JNJ) posted its quarterly earnings data on Tuesday. The company reported $1.68 EPS for the quarter, beating analysts’ consensus estimates of $1.66 by $0.02. The business had revenue of $17.80 billion for the quarter, compared to analyst estimates of $17.71 billion. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. The business’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.49 earnings per share. Johnson & Johnson updated its FY16 guidance to $6.68-6.73 EPS.

Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.550% on Wednesday, hitting $114.775. The stock had a trading volume of 6,148,276 shares. Johnson & Johnson has a 1-year low of $94.28 and a 1-year high of $126.07. The stock has a market cap of $314.01 billion, a P/E ratio of 21.389 and a beta of 0.62. The firm’s 50-day moving average is $118.58 and its 200 day moving average is $117.61.

Earnings History for Johnson & Johnson (NYSE:JNJ)

In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 2,935 shares of the business’s stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $125.01, for a total value of $366,904.35. Following the transaction, the chief accounting officer now owns 28,660 shares in the company, valued at $3,582,786.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Dominic J. Caruso sold 41,146 shares of the business’s stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total value of $5,143,661.46. Following the completion of the transaction, the vice president now owns 157,819 shares in the company, valued at approximately $19,728,953.19. The disclosure for this sale can be found here. 0.11% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Americafirst Capital Management LLC bought a new stake in shares of Johnson & Johnson during the second quarter worth $101,000. Tuttle Tactical Management LLC bought a new stake in shares of Johnson & Johnson during the second quarter worth $103,000. Lenox Wealth Management Inc. boosted its stake in shares of Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock worth $118,000 after buying an additional 190 shares in the last quarter. Thomas J. Herzfeld Advisors Inc. boosted its stake in shares of Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock worth $122,000 after buying an additional 690 shares in the last quarter. Finally, NCM Capital Management Group Inc. bought a new stake in shares of Johnson & Johnson during the second quarter worth $127,000. Hedge funds and other institutional investors own 65.32% of the company’s stock.

A number of analysts recently commented on the company. RBC Capital Markets reaffirmed an “outperform” rating and set a $133.00 price objective (up previously from $125.00) on shares of Johnson & Johnson in a research note on Wednesday, July 20th. Leerink Swann reissued an “outperform” rating and issued a $140.00 price target (up from $125.00) on shares of Johnson & Johnson in a research note on Wednesday, July 20th. BMO Capital Markets reissued an “outperform” rating and issued a $132.00 price target on shares of Johnson & Johnson in a research note on Wednesday, July 20th. Royal Bank Of Canada raised their price target on Johnson & Johnson from $125.00 to $133.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 20th. Finally, Deutsche Bank AG reissued a “hold” rating and issued a $142.00 price target (up from $125.00) on shares of Johnson & Johnson in a research note on Thursday, July 21st. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $120.12.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.